Radiation therapy and cardiac death in long-term survivors of esophageal cancer: An analysis of the surveillance, epidemiology, and end result database

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Gharzai, Laila ^a   Verma, Vivek ^a   Denniston, Kyle A ^a,b   Bhirud, Abhijeet R ^a   Bennion, Nathan R ^a   Lin, Chi ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b St Peter's Home Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVOR; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; HEART DEATH; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT RESPONSE; TREND STUDY; TUMOR LOCALIZATION; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DEATH; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; SURVIVAL ANALYSIS; SURVIVOR;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; DEATH; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SURVIVORS;

EID: 84979233628     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158916     Document Type: Article

References (43)

1. International Agency for Research on Cancer. (2012) Globocan 2012. [Online]. Available: "http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx" http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. Holmes RS, Vaughan TL. Epidemiology and Pathogenesis of Esophageal Cancer. Seminars in Radiation Oncology. 2007 Jan; 17(1): p. 2-9. PMID: 17185192
3. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012May 31; 366(22): p. 2074-84. doi: 10.1056/NEJMoa1112088 PMID: 22646630
4. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. [Online]. Available: "http://seer.cancer.gov/statfacts/html/esoph.html" http://seer.cancer.gov/statfacts/html/esoph.html
5. Sporn LA, Rubin P, Marder VJ, Wagner DD. Irradiation Induces Release of von Willebrand Protein from Endothelial Cells in Culture. Blood. 1984Aug; 64(2): p. 567-70. PMID: 6611184
6. Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiotherapy and Oncology. 1995; 35: p. 83-90. PMID: 7569029
7. Stewart FA, Heeneman S, te Poele J, Kruse J, Russell NS, Gijbels M, et al. Ionizing Radiation Accelerates the Development of Atherosclerotic Lesions in ApoE-/- Mice and Predisposes to an Inflammatory Plaque Phenotype Prone to Hemorrhage. Am J of Pathology. 2006 Feb; 168(2): p. 649-658.
8. Hancock SL, Donaldsson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Onc. 1993 Jul; 11(7): p. 1208-15.
9. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. Journal of Clinical Oncology. 2003 Sep 15; 21(18): p. 3431-9. PMID: 12885835
10. Rugbjerg K, Mellemkjaer L, Boice JD, Køber L, Ewertz M, Olsen JH. Cardiovascular disease in survivors of adolescent and young adult cancer: a Danish cohort study, 1943-2009. J Natl Cancer Inst. 2014 May 21; 106(6): p. 1-10.
11. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation Dose-Response Relationsihp for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncl. 2016 Jan 20; 34(3): p. 235-43.
12. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine. 2013 Mar 14; 368(11): p. 987-98. doi: 10.1056/NEJMoa1209825 PMID: 23484825
13. Onwudiwe NC, Kwok Y, Onukwugha E, Sorkin JD, Zuckerman IH, Shaya FT, et al. Cardiovascular event-free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk. Cancer Medicine. 2014 Oct; 3(5): p. 1342-1352. doi: 10.1002/cam4.283 PMID: 25044867
14. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med. 1996Aug 15; 335(7): p. 462-7. PMID: 8672151
15. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997 Jul 17; 337(3): p. 161-7. PMID: 9219702
16. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999 May 5; 281(17): p. 1623-7. PMID: 10235156
17. Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2009 Sep 1; 75(1): p. 122-8. doi: 10.1016/j.ijrobp.2008.10.075 PMID: 19327900
18. Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol. 2012 Jul; 104(1): p. 72-7. doi: 10.1016/j.radonc.2012.04.016 PMID: 22682539
19. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013Aug 1; 86 (5): p. 885-91. doi: 10.1016/j.ijrobp.2013.04.006 PMID: 23845841
20. Tait LM, Meyer JE, McSpadden E, Cheng JD, Baciewicz FA, Meropol NJ, et al. Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma. Pract Radiat Oncol. 2013 Oct-Dec; 3(4): p. 149-55.
21. Beukema JC, van Luijk P, Widder J, Langendijk JA, Muijs CT. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiotherapy and Oncology. 2015 Jan; 114(1): p. 85-90. doi: 10.1016/j.radonc.2014.11.037 PMID: 25554226
22. Frandsen J, Boothe D, Gaffney DK, Wilson BD, Lloyd S. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol. 2015 Oct; 6(5): p. 516-23. doi: 10.3978/j.issn.2078-6891.2015.040 PMID: 26487946
23. Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H, et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2013 Nov 1; 87(3): p. 487-93. doi: 10.1016/j.ijrobp.2013.07.008 PMID: 23968770
24. Hayashi K, Fujiwara Y, Nomura M, Kamata M, Kojima H, Kohzai M, et al. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol. 2015 Feb; 88(1046).
25. Vinke B. The incidental effect on the heart of x-ray irradiation. Acta Med Scand. 1962 Dec; 172: p. 711-3. PMID: 13997376
26. Mukherjee S, Aston D, Minett M, Brewster AE, Crosby TD. The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. Clin Oncol (R Coll Radiol). 2003 May; 15(3): p. 115-20.
27. Tripp P, Malhotra HK, Javle M, Shaukat A, Russo R, De Boer S, et al. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus. 2005; 18(6): p. 400-5. PMID: 16336612
28. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med. 2006 Nov; 47(11): p. 1756-62. PMID: 17079807
29. Gayed I, Gohar S, Liao Z, McAleer M, Bassett R, Yusuf SW. The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Int J Cardiovasc Imaging. 2009 Jun; 25(5): p. 487-95. doi: 10.1007/s10554-009-9440-7 PMID: 19234869
30. Jingu K, Kaneta T, Nemoto K, Ichinose A, Oikawa M, Takai Y, et al. The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys. 2006 Nov 1; 66(3): p. 845-51. PMID: 17011456
31. Zhang P, Hu X, Yue J, Meng X, Han D, Sun X, et al. Early detection of radiation-induced heart disease using (99m)Tc-MIBI SPECT gated myocardial perfusion imaging in patients with oesophageal cancer during radiotherapy. Radiother Oncol. 2015 May; 115(2): p. 171-8. doi: 10.1016/j.radonc.2015.04.009 PMID: 26072421
32. Umezawa R, Ota H, Takanami K, Ichinose A, Matsushita H, Saito H, et al. MRI findings of radiation-induced myocardial damage in patients with oesophageal cancer. Clin Radiol. 2014 Dec; 69(12): p. 1273-9. doi: 10.1016/j.crad.2014.08.010 PMID: 25246336
33. Hatakenaka M, Yonezawa M, Nonoshita T, Nakamura K, Yabuuchi H, Shioyama Y, et al. Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal cancer: magnetic resonance evaluation. Int J Radiat Oncol Biol Phys. 2012 May 1; 83(1): p. 67-73.
34. Haj Mohammad N, Kamphuis M, Hulshof MC, Lutkenhaus LJ, Gisbertz SS, Bergman JJ, et al. Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer. Radiother Oncol. 2015 Jan; 114(1): p. 91-5. doi: 10.1016/j.radonc.2014.12.005 PMID: 25630429
35. Taylor CW, Wang Z, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013. Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4): p. 845-53. doi: 10.1016/j.ijrobp.2015.07.2292 PMID: 26530753
36. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 1; 84(5): p. 1078-1085. doi: 10.1016/j.ijrobp.2012.02.015 PMID: 22867894
37. Kole TP, Aghayere O, Kwah J, Yorke ED, Goodman KA. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 1; 83(5): p. 1580-6. doi: 10.1016/j.ijrobp.2011.10.053 PMID: 22284687
38. Kataria T, Govardhan HB, Gupta D, Mohanraj U, Bisht SS, Sambasivaselli R, et al. Dosimetric comparison between Volumetric Modulated Arc Therapy (VMAT) vs Intensity Modulated Radiation Therapy (IMRT) for radiotherapy of mid esophageal carcinoma. J Cancer Res Ther. 2014 Oct-Dec; 10(4): p. 871-7. doi: 10.4103/0973-1482.138217 PMID: 25579521
39. Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, et al. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2016 May; 95(1): p. 488-97. doi: 10.1016/j.ijrobp.2015.11.043 PMID: 27084662
40. Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T, et al. Comparison of adverse effects of proton and x-ray chemoradiotherapy for esophageal cancer useing an adaptive dose-volume histogram analysis. J Radiat Res. 2015; 56(3): p. 568-76. doi: 10.1093/jrr/rrv001 PMID: 25755255
41. Akutsu Y, Yasuda S, Nagata M, Izumi Y, Okazumi S, Shimada H, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 2012 Jun; 105(8): p. 750-5. doi: 10.1002/jso.22127 PMID: 22012645
42. Eley JG, Friedrich T, Homann KL, Howell RM, Scholz M, Durante M, et al. Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy. Int J Radiat Oncol Biol Phys. 2016 May; 95(1): p. 279-86. doi: 10.1016/j.ijrobp.2016.02.032 PMID: 27084647
43. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. 2016 May; 122(10): p. 1483-501.